# Data extraction — filled (33 included SRs/MAs)

Auto-generated from `extract_sr_metadata.py` against the abstracts in
`01_revisiones_metaanalisis/`. Fields not extractable from the abstract are
marked "NR (full text needed)" — these will be completed before manuscript
submission. See `data_extraction_template.md` for field definitions.

## Summary table (sortable in Excel)

| # | Year | First author | Journal | PMID | Design | # studies | # participants | I² heterogeneity | RoB tool | GRADE | Funding | Country |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2006 | Xing | Br J Surg | 16329089 | MA | NR (full text needed) | 1273 | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 2 | 2009 | Kelly | Acad Radiol | 19345896 | SR | NR (full text needed) | 758 | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 3 | 2009 | van-Deurzen | Eur J Cancer | 19716287 | SR | NR (full text needed) | 2148 | 8.1 | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 4 | 2011 | Tan | J Surg Oncol | 21456092 | MA | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 5 | 2012 | Mamounas | J Clin Oncol | 23032615 | SR (inferred) | NR (full text needed) | 3,088 | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 6 | 2012 | Moody | Surgery | 22938899 | MA | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 7 | 2014 | Nagaraja | J Gastrointest Oncol | 24772341 | MA | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 8 | 2014 | Schipper | Eur J Radiol | 25458227 | SR | NR (full text needed) | 572 | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 9 | 2015 | Mocellin | Int J Cancer | 26084763 | MA | NR (full text needed) | 7,451 | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 10 | 2015 | van-Nijnatten | Eur J Surg Oncol | 26329781 | MA | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 11 | 2016 | El-Hage-Chehade | Am J Surg | 27671032 | MA | NR (full text needed) | 3,398 | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 12 | 2016 | Geng | PLoS One | 27606623 | MA | 16 | 1,456 | 27.5% | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 13 | 2018 | Krug | Strahlenther Onkol | 29383405 | SR | 13 | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 14 | 2018 | Tee | Br J Surg | 30311642 | MA | 13 | 1921 | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 15 | 2019 | Simons | Ann Surg | 30312200 | MA | 20 | 2217 | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 16 | 2021 | Cao | Breast | 34325383 | MA | NR (full text needed) | 3,578 | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 17 | 2021 | Samiei | JAMA Surg | 33881478 | Pooled analysis | 33 | 57,531 | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 18 | 2021 | Swarnkar | NR | 33810544 | Pooled analysis | 9 | 3000 | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 19 | 2022 | Gnant | Curr Opin Oncol | 36083127 | SR (inferred) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 20 | 2022 | Lin | Ann Surg Oncol | 35018590 | MA | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 21 | 2022 | Song | Cancer Med | 35502768 | MA | NR (full text needed) | 847 | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 22 | 2022 | Vxe1zquez | Clin Transl Oncol | 36153763 | SR | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 23 | 2023 | Banys-Paluchowski | Scand J Surg | 36642957 | SR (inferred) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 24 | 2023 | Ma | Front Oncol | 37064127 | Pooled analysis | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 25 | 2023 | Pantiora | Br J Surg | 36560842 | MA | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 26 | 2024 | deWild | Br J Surg | 38531689 | SR | 51 | 4512 | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 27 | 2024 | Vasigh | Breast J | 39742366 | MA | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 28 | 2024 | Yu | NR | 38826850 | MA | 21 | 1716 | 90 | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 29 | 2025 | Boland | Eur J Surg Oncol | 40009931 | MA | NR (full text needed) | 374 | 24.3 % | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 30 | 2025 | Ding | J Cancer Res Ther | 40317154 | Pooled analysis | 16 | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 31 | 2025 | Man | Breast Cancer | 40186790 | Pooled analysis | NR (full text needed) | 4268 | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 32 | 2025 | Wang | Oncology | 39899993 | MA | NR (full text needed) | 5,249 | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |
| 33 | 2026 | Abdulla | Ann Surg Oncol | 41545613 | MA | NR (full text needed) | 2849 | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) | NR (full text needed) |

## Per-study cards (one block per SR)

### 1. Xing 2006 — Br J Surg

- **Filename:** `2006_Xing_Meta-analisis_Br-J-Surg.md`
- **PMID:** 16329089 | **DOI:** [10.1002/bjs.5209](https://doi.org/10.1002/bjs.5209)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** MA
- **Number of included studies:** NR (full text needed)
- **Total participants:** 1273
- **Population (cN status, subtype mix):** see abstract in `2006_Xing_Meta-analisis_Br-J-Surg.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2006_Xing_Meta-analisis_Br-J-Surg.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=16329089)

### 2. Kelly 2009 — Acad Radiol

- **Filename:** `2009_Kelly_Revision-sistematica_Acad-Radiol.md`
- **PMID:** 19345896 | **DOI:** [10.1016/j.acra.2009.01.026](https://doi.org/10.1016/j.acra.2009.01.026)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** SR
- **Number of included studies:** NR (full text needed)
- **Total participants:** 758
- **Population (cN status, subtype mix):** see abstract in `2009_Kelly_Revision-sistematica_Acad-Radiol.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2009_Kelly_Revision-sistematica_Acad-Radiol.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=19345896)

### 3. van-Deurzen 2009 — Eur J Cancer

- **Filename:** `2009_van-Deurzen_Revision-sistematica_Eur-J-Cancer.md`
- **PMID:** 19716287 | **DOI:** [10.1016/j.ejca.2009.08.001](https://doi.org/10.1016/j.ejca.2009.08.001)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** SR
- **Number of included studies:** NR (full text needed)
- **Total participants:** 2148
- **Population (cN status, subtype mix):** see abstract in `2009_van-Deurzen_Revision-sistematica_Eur-J-Cancer.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** 8.1
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2009_van-Deurzen_Revision-sistematica_Eur-J-Cancer.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=19716287)

### 4. Tan 2011 — J Surg Oncol

- **Filename:** `2011_Tan_Meta-analisis_J-Surg-Oncol.md`
- **PMID:** 21456092 | **DOI:** [10.1002/jso.21911](https://doi.org/10.1002/jso.21911)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** MA
- **Number of included studies:** NR (full text needed)
- **Total participants:** NR (full text needed)
- **Population (cN status, subtype mix):** see abstract in `2011_Tan_Meta-analisis_J-Surg-Oncol.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2011_Tan_Meta-analisis_J-Surg-Oncol.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=21456092)

### 5. Mamounas 2012 — J Clin Oncol

- **Filename:** `2012_Mamounas_Radioterapia-NAC_J-Clin-Oncol.md`
- **PMID:** 23032615 | **DOI:** [10.1200/JCO.2011.40.8369](https://doi.org/10.1200/JCO.2011.40.8369)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** SR (inferred)
- **Number of included studies:** NR (full text needed)
- **Total participants:** 3,088
- **Population (cN status, subtype mix):** see abstract in `2012_Mamounas_Radioterapia-NAC_J-Clin-Oncol.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2012_Mamounas_Radioterapia-NAC_J-Clin-Oncol.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=23032615)

### 6. Moody 2012 — Surgery

- **Filename:** `2012_Moody_Meta-analisis_Surgery.md`
- **PMID:** 22938899 | **DOI:** [10.1016/j.surg.2012.06.017](https://doi.org/10.1016/j.surg.2012.06.017)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** MA
- **Number of included studies:** NR (full text needed)
- **Total participants:** NR (full text needed)
- **Population (cN status, subtype mix):** see abstract in `2012_Moody_Meta-analisis_Surgery.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2012_Moody_Meta-analisis_Surgery.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=22938899)

### 7. Nagaraja 2014 — J Gastrointest Oncol

- **Filename:** `2014_Nagaraja_Meta-analisis_J-Gastrointest-Oncol.md`
- **PMID:** 24772341 | **DOI:** [10.3978/j.issn.2078-6891.2014.008](https://doi.org/10.3978/j.issn.2078-6891.2014.008)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** MA
- **Number of included studies:** NR (full text needed)
- **Total participants:** NR (full text needed)
- **Population (cN status, subtype mix):** see abstract in `2014_Nagaraja_Meta-analisis_J-Gastrointest-Oncol.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2014_Nagaraja_Meta-analisis_J-Gastrointest-Oncol.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=24772341)

### 8. Schipper 2014 — Eur J Radiol

- **Filename:** `2014_Schipper_Revision-sistematica_Eur-J-Radiol.md`
- **PMID:** 25458227 | **DOI:** [10.1016/j.ejrad.2014.09.020](https://doi.org/10.1016/j.ejrad.2014.09.020)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** SR
- **Number of included studies:** NR (full text needed)
- **Total participants:** 572
- **Population (cN status, subtype mix):** see abstract in `2014_Schipper_Revision-sistematica_Eur-J-Radiol.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2014_Schipper_Revision-sistematica_Eur-J-Radiol.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=25458227)

### 9. Mocellin 2015 — Int J Cancer

- **Filename:** `2015_Mocellin_Meta-analisis_Int-J-Cancer.md`
- **PMID:** 26084763 | **DOI:** [10.1002/ijc.29644](https://doi.org/10.1002/ijc.29644)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** MA
- **Number of included studies:** NR (full text needed)
- **Total participants:** 7,451
- **Population (cN status, subtype mix):** see abstract in `2015_Mocellin_Meta-analisis_Int-J-Cancer.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2015_Mocellin_Meta-analisis_Int-J-Cancer.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=26084763)

### 10. van-Nijnatten 2015 — Eur J Surg Oncol

- **Filename:** `2015_van-Nijnatten_Meta-analisis_Eur-J-Surg-Oncol.md`
- **PMID:** 26329781 | **DOI:** [10.1016/j.ejso.2015.07.020](https://doi.org/10.1016/j.ejso.2015.07.020)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** MA
- **Number of included studies:** NR (full text needed)
- **Total participants:** NR (full text needed)
- **Population (cN status, subtype mix):** see abstract in `2015_van-Nijnatten_Meta-analisis_Eur-J-Surg-Oncol.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2015_van-Nijnatten_Meta-analisis_Eur-J-Surg-Oncol.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=26329781)

### 11. El-Hage-Chehade 2016 — Am J Surg

- **Filename:** `2016_El-Hage-Chehade_Meta-analisis_Am-J-Surg.md`
- **PMID:** 27671032 | **DOI:** [10.1016/j.amjsurg.2016.07.018](https://doi.org/10.1016/j.amjsurg.2016.07.018)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** MA
- **Number of included studies:** NR (full text needed)
- **Total participants:** 3,398
- **Population (cN status, subtype mix):** see abstract in `2016_El-Hage-Chehade_Meta-analisis_Am-J-Surg.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2016_El-Hage-Chehade_Meta-analisis_Am-J-Surg.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=27671032)

### 12. Geng 2016 — PLoS One

- **Filename:** `2016_Geng_Meta-analisis_PLoS-One.md`
- **PMID:** 27606623 | **DOI:** [10.1371/journal.pone.0162605](https://doi.org/10.1371/journal.pone.0162605)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** MA
- **Number of included studies:** 16
- **Total participants:** 1,456
- **Population (cN status, subtype mix):** see abstract in `2016_Geng_Meta-analisis_PLoS-One.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** 27.5%
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2016_Geng_Meta-analisis_PLoS-One.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=27606623)

### 13. Krug 2018 — Strahlenther Onkol

- **Filename:** `2018_Krug_Revision-sistematica_Strahlenther-Onkol.md`
- **PMID:** 29383405 | **DOI:** [10.1007/s00066-018-1270-x](https://doi.org/10.1007/s00066-018-1270-x)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** SR
- **Number of included studies:** 13
- **Total participants:** NR (full text needed)
- **Population (cN status, subtype mix):** see abstract in `2018_Krug_Revision-sistematica_Strahlenther-Onkol.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2018_Krug_Revision-sistematica_Strahlenther-Onkol.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=29383405)

### 14. Tee 2018 — Br J Surg

- **Filename:** `2018_Tee_Meta-analisis_Br-J-Surg.md`
- **PMID:** 30311642 | **DOI:** [10.1002/bjs.10986](https://doi.org/10.1002/bjs.10986)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** MA
- **Number of included studies:** 13
- **Total participants:** 1921
- **Population (cN status, subtype mix):** see abstract in `2018_Tee_Meta-analisis_Br-J-Surg.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2018_Tee_Meta-analisis_Br-J-Surg.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=30311642)

### 15. Simons 2019 — Ann Surg

- **Filename:** `2019_Simons_Meta-analisis_Ann-Surg.md`
- **PMID:** 30312200 | **DOI:** [10.1097/SLA.0000000000003075](https://doi.org/10.1097/SLA.0000000000003075)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** MA
- **Number of included studies:** 20
- **Total participants:** 2217
- **Population (cN status, subtype mix):** see abstract in `2019_Simons_Meta-analisis_Ann-Surg.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2019_Simons_Meta-analisis_Ann-Surg.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=30312200)

### 16. Cao 2021 — Breast

- **Filename:** `2021_Cao_Meta-analisis_Breast.md`
- **PMID:** 34325383 | **DOI:** [10.1016/j.breast.2021.07.015](https://doi.org/10.1016/j.breast.2021.07.015)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** MA
- **Number of included studies:** NR (full text needed)
- **Total participants:** 3,578
- **Population (cN status, subtype mix):** see abstract in `2021_Cao_Meta-analisis_Breast.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2021_Cao_Meta-analisis_Breast.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=34325383)

### 17. Samiei 2021 — JAMA Surg

- **Filename:** `2021_Samiei_Axillary-pCR-by-subtype_JAMA-Surg.md`
- **PMID:** 33881478 | **DOI:** [10.1001/jamasurg.2021.0891](https://doi.org/10.1001/jamasurg.2021.0891)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** Pooled analysis
- **Number of included studies:** 33
- **Total participants:** 57,531
- **Population (cN status, subtype mix):** see abstract in `2021_Samiei_Axillary-pCR-by-subtype_JAMA-Surg.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2021_Samiei_Axillary-pCR-by-subtype_JAMA-Surg.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=33881478)

### 18. Swarnkar 2021 — NR

- **Filename:** `2021_Swarnkar_MLNB-TAD-pooled_Cancers.md`
- **PMID:** 33810544 | **DOI:** [10.3390/cancers13071539](https://doi.org/10.3390/cancers13071539)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** Pooled analysis
- **Number of included studies:** 9
- **Total participants:** 3000
- **Population (cN status, subtype mix):** see abstract in `2021_Swarnkar_MLNB-TAD-pooled_Cancers.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2021_Swarnkar_MLNB-TAD-pooled_Cancers.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=33810544)

### 19. Gnant 2022 — Curr Opin Oncol

- **Filename:** `2022_Gnant_Breast-surgery-after-NAT_Curr-Opin-Oncol.md`
- **PMID:** 36083127 | **DOI:** [10.1097/CCO.0000000000000906](https://doi.org/10.1097/CCO.0000000000000906)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** SR (inferred)
- **Number of included studies:** NR (full text needed)
- **Total participants:** NR (full text needed)
- **Population (cN status, subtype mix):** see abstract in `2022_Gnant_Breast-surgery-after-NAT_Curr-Opin-Oncol.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2022_Gnant_Breast-surgery-after-NAT_Curr-Opin-Oncol.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=36083127)

### 20. Lin 2022 — Ann Surg Oncol

- **Filename:** `2022_Lin_Meta-analisis_Ann-Surg-Oncol.md`
- **PMID:** 35018590 | **DOI:** [10.1245/s10434-021-11297-z](https://doi.org/10.1245/s10434-021-11297-z)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** MA
- **Number of included studies:** NR (full text needed)
- **Total participants:** NR (full text needed)
- **Population (cN status, subtype mix):** see abstract in `2022_Lin_Meta-analisis_Ann-Surg-Oncol.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2022_Lin_Meta-analisis_Ann-Surg-Oncol.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=35018590)

### 21. Song 2022 — Cancer Med

- **Filename:** `2022_Song_Meta-analisis_Cancer-Med.md`
- **PMID:** 35502768 | **DOI:** [10.1002/cam4.4769](https://doi.org/10.1002/cam4.4769)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** MA
- **Number of included studies:** NR (full text needed)
- **Total participants:** 847
- **Population (cN status, subtype mix):** see abstract in `2022_Song_Meta-analisis_Cancer-Med.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2022_Song_Meta-analisis_Cancer-Med.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=35502768)

### 22. Vxe1zquez 2022 — Clin Transl Oncol

- **Filename:** `2022_Vxe1zquez_Revision-sistematica_Clin-Transl-Oncol.md`
- **PMID:** 36153763 | **DOI:** [10.1007/s12094-022-02953-1](https://doi.org/10.1007/s12094-022-02953-1)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** SR
- **Number of included studies:** NR (full text needed)
- **Total participants:** NR (full text needed)
- **Population (cN status, subtype mix):** see abstract in `2022_Vxe1zquez_Revision-sistematica_Clin-Transl-Oncol.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2022_Vxe1zquez_Revision-sistematica_Clin-Transl-Oncol.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=36153763)

### 23. Banys-Paluchowski 2023 — Scand J Surg

- **Filename:** `2023_Banys-Paluchowski_Axillary-staging-cN-to-ycN0_Scand-J-Surg.md`
- **PMID:** 36642957 | **DOI:** [10.1177/14574969221145892](https://doi.org/10.1177/14574969221145892)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** SR (inferred)
- **Number of included studies:** NR (full text needed)
- **Total participants:** NR (full text needed)
- **Population (cN status, subtype mix):** see abstract in `2023_Banys-Paluchowski_Axillary-staging-cN-to-ycN0_Scand-J-Surg.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2023_Banys-Paluchowski_Axillary-staging-cN-to-ycN0_Scand-J-Surg.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=36642957)

### 24. Ma 2023 — Front Oncol

- **Filename:** `2023_Ma_Meta-analisis_Front-Oncol.md`
- **PMID:** 37064127 | **DOI:** [10.3389/fonc.2023.1167912](https://doi.org/10.3389/fonc.2023.1167912)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** Pooled analysis
- **Number of included studies:** NR (full text needed)
- **Total participants:** NR (full text needed)
- **Population (cN status, subtype mix):** see abstract in `2023_Ma_Meta-analisis_Front-Oncol.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2023_Ma_Meta-analisis_Front-Oncol.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=37064127)

### 25. Pantiora 2023 — Br J Surg

- **Filename:** `2023_Pantiora_Meta-analisis_Br-J-Surg.md`
- **PMID:** 36560842 | **DOI:** [10.1093/bjs/znac426](https://doi.org/10.1093/bjs/znac426)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** MA
- **Number of included studies:** NR (full text needed)
- **Total participants:** NR (full text needed)
- **Population (cN status, subtype mix):** see abstract in `2023_Pantiora_Meta-analisis_Br-J-Surg.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2023_Pantiora_Meta-analisis_Br-J-Surg.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=36560842)

### 26. deWild 2024 — Br J Surg

- **Filename:** `2024_deWild_TAD-systematic-review_BJS.md`
- **PMID:** 38531689 | **DOI:** [10.1093/bjs/znae071](https://doi.org/10.1093/bjs/znae071)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** SR
- **Number of included studies:** 51
- **Total participants:** 4512
- **Population (cN status, subtype mix):** see abstract in `2024_deWild_TAD-systematic-review_BJS.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2024_deWild_TAD-systematic-review_BJS.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=38531689)

### 27. Vasigh 2024 — Breast J

- **Filename:** `2024_Vasigh_NET-vs-NAC-cN-positive_Breast-J.md`
- **PMID:** 39742366 | **DOI:** [10.1155/2024/8866756](https://doi.org/10.1155/2024/8866756)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** MA
- **Number of included studies:** NR (full text needed)
- **Total participants:** NR (full text needed)
- **Population (cN status, subtype mix):** see abstract in `2024_Vasigh_NET-vs-NAC-cN-positive_Breast-J.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2024_Vasigh_NET-vs-NAC-cN-positive_Breast-J.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=39742366)

### 28. Yu 2024 — NR

- **Filename:** `2024_Yu_Meta-analisis_Breast-Cancer-Auckl.md`
- **PMID:** 38826850 | **DOI:** [10.1177/11782234241255856](https://doi.org/10.1177/11782234241255856)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** MA
- **Number of included studies:** 21
- **Total participants:** 1716
- **Population (cN status, subtype mix):** see abstract in `2024_Yu_Meta-analisis_Breast-Cancer-Auckl.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** 90
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2024_Yu_Meta-analisis_Breast-Cancer-Auckl.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=38826850)

### 29. Boland 2025 — Eur J Surg Oncol

- **Filename:** `2025_Boland_Meta-analisis_Eur-J-Surg-Oncol.md`
- **PMID:** 40009931 | **DOI:** [10.1016/j.ejso.2025.109684](https://doi.org/10.1016/j.ejso.2025.109684)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** MA
- **Number of included studies:** NR (full text needed)
- **Total participants:** 374
- **Population (cN status, subtype mix):** see abstract in `2025_Boland_Meta-analisis_Eur-J-Surg-Oncol.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** 24.3 %
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2025_Boland_Meta-analisis_Eur-J-Surg-Oncol.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=40009931)

### 30. Ding 2025 — J Cancer Res Ther

- **Filename:** `2025_Ding_Meta-analisis_J-Cancer-Res-Ther.md`
- **PMID:** 40317154 | **DOI:** [10.4103/jcrt.jcrt_1279_24](https://doi.org/10.4103/jcrt.jcrt_1279_24)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** Pooled analysis
- **Number of included studies:** 16
- **Total participants:** NR (full text needed)
- **Population (cN status, subtype mix):** see abstract in `2025_Ding_Meta-analisis_J-Cancer-Res-Ther.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2025_Ding_Meta-analisis_J-Cancer-Res-Ther.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=40317154)

### 31. Man 2025 — Breast Cancer

- **Filename:** `2025_Man_Meta-analisis_Breast-Cancer.md`
- **PMID:** 40186790 | **DOI:** [10.1007/s12282-025-01692-9](https://doi.org/10.1007/s12282-025-01692-9)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** Pooled analysis
- **Number of included studies:** NR (full text needed)
- **Total participants:** 4268
- **Population (cN status, subtype mix):** see abstract in `2025_Man_Meta-analisis_Breast-Cancer.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2025_Man_Meta-analisis_Breast-Cancer.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=40186790)

### 32. Wang 2025 — Oncology

- **Filename:** `2025_Wang_Meta-analisis_Oncology.md`
- **PMID:** 39899993 | **DOI:** [10.1159/000543662](https://doi.org/10.1159/000543662)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** MA
- **Number of included studies:** NR (full text needed)
- **Total participants:** 5,249
- **Population (cN status, subtype mix):** see abstract in `2025_Wang_Meta-analisis_Oncology.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2025_Wang_Meta-analisis_Oncology.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=39899993)

### 33. Abdulla 2026 — Ann Surg Oncol

- **Filename:** `2026_Abdulla_Meta-analisis_Ann-Surg-Oncol.md`
- **PMID:** 41545613 | **DOI:** [10.1245/s10434-025-19070-2](https://doi.org/10.1245/s10434-025-19070-2)
- **Country (corresponding author):** NR (full text needed)
- **Review design:** MA
- **Number of included studies:** NR (full text needed)
- **Total participants:** 2849
- **Population (cN status, subtype mix):** see abstract in `2026_Abdulla_Meta-analisis_Ann-Surg-Oncol.md`
- **Intervention(s) / comparator(s):** see abstract
- **Primary outcome reported:** see abstract
- **Pooled estimate (point + 95% CI):** NR (full text needed) — abstracts give qualitative summary only
- **Heterogeneity (I², τ², χ²):** NR (full text needed)
- **Risk-of-bias tool:** NR (full text needed)
- **GRADE reported:** NR (full text needed)
- **Funding source:** NR (full text needed)
- **Authors' main conclusion:** see abstract / Relevancia section in `2026_Abdulla_Meta-analisis_Ann-Surg-Oncol.md`
- **AMSTAR-2 overall confidence:** see `02_amstar2/amstar2_scores.csv` (row PMID=41545613)

---

## Most common "NR (full text needed)" fields

- **rob_tool**: NR in 33/33 (100%)
- **grade_reported**: NR in 33/33 (100%)
- **funding**: NR in 33/33 (100%)
- **country**: NR in 33/33 (100%)
- **i2_heterogeneity**: NR in 29/33 (88%)
- **n_included_studies**: NR in 24/33 (73%)
- **n_participants**: NR in 13/33 (39%)